Observational study of BPDCN patients treated with chemotherapy
Part of Blood & lymphatic, Cancer, Skin clinical trials.
This study looks back at the health records of people who were treated for BPDCN (a rare blood cancer) with chemotherapy as their first treatment. The goal is to learn more about how the disease progresses and how well treatments work in the real world. If you meet the criteria, your past medical data may be included.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with BPDCN.
- You must be 18 or older when you started your first treatment.
- Your first treatment must have been chemotherapy, not an experimental drug.
- Your treatment must have started on or after May 2016.
- You must be willing to allow access to your medical records (if you are still alive) or have your family's permission for a retrospective review if deceased.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with a rare blood cancer called BPDCN who are starting or recently started a medicine called Elzonris (tagraxofusp). It collects health information to see how the treatment works over time.
This trial tests a combination of two targeted drugs (tagraxofusp and venetoclax) for people with a rare blood cancer called BPDCN who have not been treated before. The goal is to see if this combination is safe and effective as a first treatment.
This Phase 2 trial tests venetoclax combined with chemotherapy to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). It may help shrink BPDCN and control the disease, whether you’re newly diagnosed or the cancer has come back.
This study checks whether a blood test that looks for “tumor DNA” (circulating tumor DNA) can help evaluate how well neoadjuvant chemotherapy worked for breast cancer. It may help doctors better understand treatment response after surgery.
This trial tests a new drug called BCD-236 combined with chemotherapy for people with triple-negative breast cancer that has come back or spread. It may be an option if your cancer is AXL-positive and you have tried at least one prior treatment.
This study tests whether a blood test (ctDNA) can help doctors see how well treatment is working for people with a type of brain lymphoma (PCNSL) who are getting their first treatment with a cure in mind.
Hear when a new Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.